ALPN-202

DRUG2 trials

Sponsors

Alpine Immune Sciences, Inc.

Conditions

Advanced Solid TumorLymphoma

Phase 1

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

TerminatedNCT04186637

Alpine Immune Sciences, Inc.Advanced Solid Tumor, Lymphoma

Start: 2020-06-02End: 2023-02-28Updated: 2023-06-05

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

TerminatedNCT04920383

Alpine Immune Sciences, Inc.Advanced Solid Tumor, Lymphoma

Start: 2021-06-22End: 2023-02-28Updated: 2024-03-01

Related Papers

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

Journal for ImmunoTherapy of Cancer2024-08-019 citations

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab

Journal for ImmunoTherapy of Cancer2024-08-018 citations

738 Interim dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in advanced malignancies (NEON-2)

Regular and Young Investigator Award Abstracts2022-11-01

Abstract CT041: Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)

Cancer Research2022-06-151 citations

Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).

Journal of Clinical Oncology2022-06-012 citations

Davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in patients with advanced malignancies (NEON-2).

Journal of Clinical Oncology2022-06-011 citations

497 A Study of ALPN-202, a PD-L1-dependent CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in patients with advanced malignancies

Regular and Young Investigator Award Abstracts2021-11-01

33 Development of a clinical <i>ex vivo</i> assay for the assessment of therapeutic CD28 costimulatory pathway engagement

Regular and Young Investigator Award Abstracts2021-11-01

Abstract CT213: NEON-1: a first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Cancer Research2021-07-01

First-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies.

Journal of Clinical Oncology2021-05-201 citations

Abstract CT245: NEON-1: A first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Cancer Research2020-08-15